Literature DB >> 2673082

A 10-year experience with 290 pancreas transplants at a single institution.

D E Sutherland1, D L Dunn, F C Goetz, W Kennedy, R C Ramsay, M W Steffes, S M Mauer, R Gruessner, K C Moudry-Munns, P Morel.   

Abstract

Since our report at the 1984 American Surgical Association meeting of 100 pancreas transplants from 1966 through 1983, another 190 have been performed. The current series, begun in 1978, now numbers 276 cases, and includes 133 nonuremic recipients of pancreas transplants alone (PTA), 46 simultaneous pancreas/kidney transplants (SPK), and 97 pancreas tranplants after a kidney transplant (PAK). Duct management techniques used were free intraperitoneal drainage in 44 cases, duct occlusion in 44, enteric drainage in 89, and bladder drainage in 128. The 1-year patient and graft survival rates in the entire cohort of 276 were 91% and 42%. One-year patient survival rates were 88% in the first 100, 91% in the second 100, and 92% in the last 76 cases; corresponding 1-year graft survival rates were 28%, 47%, and 56% (p less than 0.05). A prospective comparison of bladder drainage (n = 82) versus enteric drainage (n = 46) in PAK/PTA cases since November 1, 1984 favored bladder drainage (1-year graft survival rates of 52% vs. 41%) because of urinary amylase monitoring. The best results were in recipients of primary SPK bladder-drained transplants (n = 39), with a 1-year pancreas graft survival rate of 75%, kidney graft survival rate of 80%, and patient survival rate of 95%. Logistic regression analysis, with 1-year graft function as the independent variable, showed significant (p less than 0.05) predictors of success (odds ratio) to be technique: bladder drainage (5.8) versus enteric drainage (2.5) versus duct injection (1.0); category: SPK (6.0) versus PAK from same donor (3.2) versus PAK from different donor (1.2) versus PTA (1.0); and donor HLA DR mismatch: 0 (5.0) versus 1 (2.5) versus 2 (1.0) antigens. On April 1, 1989, 90 patients had functioning grafts (60 euglycemic and insulin-free for more than 1 year, 10 for 5 to 10 years); these, along with 24 others whose grafts functioned for 1 to 6 years before failing, are part of an expanding cohort in whom the influence of inducing a euglycemic state on pre-existing secondary complications of diabetes is being studied. Only preliminary data is available. In regard to neuropathy, at more than 1 year after transplant in patients with functioning grafts, conduction velocities in some nerves were increased over baseline. In regard to retinopathy, deterioration in grade occurred in approximately 30% of the recipients by 3 years, whether the graft functioned continuously or failed early, but thereafter retinopathy in the patients with functioning grafts remained stable.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2673082      PMCID: PMC1357985          DOI: 10.1097/00000658-198909000-00003

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  58 in total

1.  Specific immunological tolerance/optimal graft function in the absence of immunosuppressive therapy.

Authors:  L Burrows; L Reisman; H Schanzer; S Kupfer
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

2.  Is HLA matching relevant in pancreas transplantation? A registry analysis.

Authors:  J P Squifflet; K Moudry; D E Sutherland
Journal:  Transpl Int       Date:  1988-04       Impact factor: 3.782

Review 3.  Metabolic effect of hemipancreatectomy in donors. Preoperative prediction of postoperative oral glucose tolerance.

Authors:  D M Kendall; D E Sutherland; F C Goetz; J S Najarian
Journal:  Diabetes       Date:  1989-01       Impact factor: 9.461

4.  Rejection of kidney and pancreas after pancreas-kidney transplantation.

Authors:  R Margreiter; G Klima; C Bösmüller; A Königsrainer; T Schmid; E Steiner
Journal:  Diabetes       Date:  1989-01       Impact factor: 9.461

5.  Intraperitoneal transplantation of immediately vascularized segmental pancreatic grafts without duct ligation. A clinical trial.

Authors:  D E Sutherland; F C Goetz; J S Najarian
Journal:  Transplantation       Date:  1979-12       Impact factor: 4.939

6.  Recurrent diabetic nephropathy in renal allografts placed in diabetic patients and protective effect of simultaneous pancreatic transplantation.

Authors:  S O Bohman; H Wilczek; G Tydén; G Jaremko; G Lundgren; C G Groth
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

7.  Pancreas transplantation with pancreaticocystostomy and quadruple immunosuppression.

Authors:  H W Sollinger; R J Stratta; M Kalayoglu; J D Pirsch; F O Belzer
Journal:  Surgery       Date:  1987-10       Impact factor: 3.982

8.  Transplantation of the pancreas.

Authors:  R C Lillehei; J O Ruix; C Aquino; F Goetz
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1976

9.  Surgical treatment of diabetic nephropathy with simultaneous pancreatic duodenal and renal transplantation.

Authors:  R J Corry; D D Nghiem; J A Schulak; W D Beutel; T A Gonwa
Journal:  Surg Gynecol Obstet       Date:  1986-06

10.  Function of transplanted human pancreatic allografts after preservation in cold storage for 6 to 26 hours.

Authors:  G M Abouna; D E Sutherland; G Florack; J S Najarian
Journal:  Transplantation       Date:  1987-05       Impact factor: 4.939

View more
  18 in total

Review 1.  Pancreatic transplantation: why, when and who?

Authors:  P J Lefèbvre
Journal:  Diabetologia       Date:  1992-05       Impact factor: 10.122

Review 2.  Pancreas transplantation: indications and outcomes.

Authors:  D E Sutherland
Journal:  Acta Diabetol       Date:  1992       Impact factor: 4.280

3.  Time-related, cross-sectional and prospective follow-up of pancreatic endocrine function after pancreas allograft transplantation in type 1 (insulin-dependent) diabetic patients.

Authors:  R P Robertson; P Diem; D E Sutherland
Journal:  Diabetologia       Date:  1991-08       Impact factor: 10.122

Review 4.  Lessons learned from more than 1,000 pancreas transplants at a single institution.

Authors:  D E Sutherland; R W Gruessner; D L Dunn; A J Matas; A Humar; R Kandaswamy; S M Mauer; W R Kennedy; F C Goetz; R P Robertson; A C Gruessner; J S Najarian
Journal:  Ann Surg       Date:  2001-04       Impact factor: 12.969

Review 5.  Pancreas transplantation.

Authors:  R J Stratta; R J Taylor; J L Larsen; K Cushing
Journal:  Int J Pancreatol       Date:  1995-02

6.  Donor hyperglycemia as a minor risk factor and immunologic variables as major risk factors for pancreas allograft loss in a multivariate analysis of a single institution's experience.

Authors:  P F Gores; K J Gillingham; D L Dunn; K C Moudry-Munns; J S Najarian; D E Sutherland
Journal:  Ann Surg       Date:  1992-03       Impact factor: 12.969

Review 7.  Islet transplantation a decade later and strategies for filling a half-full glass.

Authors:  R Paul Robertson
Journal:  Diabetes       Date:  2010-06       Impact factor: 9.461

8.  Quality of life of pancreas transplant recipients.

Authors:  C L Zehrer; C R Gross
Journal:  Diabetologia       Date:  1991-08       Impact factor: 10.122

9.  The bladder drainage technique in pancreas transplantation--the Tübingen experience.

Authors:  U T Hopt; M Büsing; W D Schareck; H D Becker
Journal:  Diabetologia       Date:  1991-08       Impact factor: 10.122

10.  Duodenal segment complications in vascularized pancreas transplantation.

Authors:  R J Stratta; R Sindhi; D Sudan; J T Jerius; S J Radio
Journal:  J Gastrointest Surg       Date:  1997 Nov-Dec       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.